Pulmonology Book

http://www.fpnotebook.com/

Omalizumab

Aka: Omalizumab, rhuMAb-E25
  1. Indications (all required)
    1. Refractory moderate to Severe Persistent Asthma
    2. Positive Allergy Testing for perennial inhaled allergen
    3. Patients must be age 12 years or over
  2. Mechanism
    1. Recombinant humanized Monoclonal Antibody (rhu-MAB)
    2. Blocks IgE binding to mast cells and Basophils
      1. Prevents release of Allergic Reaction mediators
  3. Adverse effects
    1. Serious and life-threatening
      1. May predispose to malignancy
      2. Anaphylaxis
        1. Requires administration in clinical setting
        2. Reaction may occur within 2 hours of injection
    2. Other reactions
      1. Injection site reaction
      2. Upper Respiratory Infections (including Sinusitis, Pharyngitis)
      3. Headache
  4. Efficacy
    1. Appears to be very effective in first year of use
  5. Cost
    1. Dose dependent
    2. Varies from $500 to over $3000 for one month supply
  6. Dosing
    1. Dose determined by serum IgE level
    2. Usually 150 to 375 mg SQ every 2-4 weeks
    3. Must be given in clinical setting with observation
  7. References
    1. Finn (2003) J Allergy Clin Immunol 111:278-84 [PubMed]

omalizumab (C0966225)

Definition (NCI) A humanized monoclonal antibody directed against the C-epsilon 3 domain of immunoglobulin E. Olizumab binds to this IgE domain, thereby preventing IgE from binding to its high-affinity mast-cell receptor. (NCI04)
Concepts Immunologic Factor (T129) , Amino Acid, Peptide, or Protein (T116) , Pharmacologic Substance (T121)
MSH C426106
SnomedCT 406442003, 406443008
English omalizumab (medication), OMALIZUMAB, Olizumab, omalizumab [Chemical/Ingredient], Immunoglobulin G, anti-(human immunoglobulin E Fc region)(human-mouse monoclonal E25 clone pSVIE26 gamma-chain), disulfide with human-mouse monoclonal E25 clone pSVIE26 kappa-chain, dimer, omalizumab, Omalizumab, Omalizumab (product), Omalizumab (substance)
Spanish omalizumab (producto), omalizumab (sustancia), omalizumab
Sources
Derived from the NIH UMLS (Unified Medical Language System)


You are currently viewing the original 'fpnotebook.com\legacy' version of this website. Internet Explorer 8.0 and older will automatically be redirected to this legacy version.

If you are using a modern web browser, you may instead navigate to the newer desktop version of fpnotebook. Another, mobile version is also available which should function on both newer and older web browsers.

Please Contact Me as you run across problems with any of these versions on the website.

Navigation Tree